Skip to main content
    I

    Incyte Corporation (INCY)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $113.27
    +1.70 (+1.52%)

    Market Cap: $22.61B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    51%(20/39)
    Avg Surprise
    -4.59%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-3.63
    Range$-4.24 - $-2.84
    16 analysts
    EPS Revisions
    3
    0
    7d
    0
    8
    30d
    EPS Estimate DriftChange to current
    90d ago$-2.34-54.8%
    60d ago$-3.39-6.9%
    30d ago$-3.47-4.4%
    7d ago$-3.51-3.4%
    Current$-3.63
    Revenue Consensus
    $1.5B
    Range$1.4B - $1.5B
    20 analysts
    Period ending Dec 31, 2026
    EPS Consensus$3.43
    Range$2.45 - $4.29
    19 analysts
    Revenue Consensus
    $1.8B
    Range$1.7B - $1.8B
    23 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$3.43---
    Sep 26EST
    		-$-3.63---
    Jun 26
    Reported Jul 28
    		$2.80$1.76+59.09%Beat+78.3%
    Mar 26
    Reported Apr 28
    		$1.81$1.34+35.07%Beat+56.0%
    Dec 25
    Reported Feb 10
    		$1.80$1.92-6.25%Miss+25.9%
    Sep 25
    Reported Oct 28
    		$2.26$1.64+37.80%Beat+111.2%
    Jun 25
    Reported Jul 29
    		$1.57$1.47+6.80%Beat+186.3%
    Mar 25
    Reported Apr 29
    		$1.16$1.03+12.62%Beat+81.2%
    Dec 24
    Reported Feb 10
    		$1.43$1.55-7.74%Miss+34.9%
    Sep 24
    Reported Oct 29
    		$1.07$1.09-1.83%Miss-2.7%
    Jun 24
    Reported Jul 30
    		$-1.82$1.11-263.96%Miss-283.8%
    Mar 24
    Reported Apr 30
    		$0.64$0.83-22.89%Miss+73.0%
    Dec 23
    Reported Feb 13
    		$1.06$1.15-7.83%Miss+71.0%
    Sep 23
    Reported Oct 31
    		$1.10$1.07+2.80%Beat+83.3%
    Jun 23
    Reported Aug 1
    		$0.99$0.87+13.79%Beat-2.0%
    Mar 23
    Reported May 2
    		$0.37$0.74-50.00%Miss-32.7%
    Dec 22
    Reported Feb 7
    		$0.62$0.57+8.77%Beat+520.0%
    Sep 22
    Reported Nov 1
    		$0.60$0.71-15.49%Miss-49.2%
    Jun 22
    Reported Aug 2
    		$1.01$0.75+34.67%Beat+26.2%
    Mar 22
    Reported May 3
    		$0.55$0.69-20.29%Miss-17.9%
    Dec 21
    Reported Feb 8
    		$0.10N/A-88.51%Miss-89.2%
    Sep 21
    Reported Nov 2
    		$1.18$0.76+55.26%Beat+413.0%
    Jun 21
    Reported Aug 3
    		$0.80$0.74+8.11%Beat-35.5%
    Mar 21
    Reported May 4
    		$0.67$0.64+4.69%Beat+123.4%
    Dec 20
    Reported Feb 9
    		$0.93$0.77+20.78%Beat+43.1%
    Sep 20
    Reported Nov 5
    		$0.23N/A-69.74%Miss-72.0%
    Jun 20
    Reported Aug 4
    		$1.24$0.86+44.19%Beat+65.3%
    Mar 20
    Reported May 5
    		$-2.86$-2.80-2.14%Miss-561.3%
    Dec 19
    Reported Feb 13
    		$0.65$0.58+12.07%Beat+62.5%
    Sep 19
    Reported Oct 29
    		$0.82$0.64+28.13%Beat+115.8%
    Jun 19
    Reported Jul 30
    		$0.75$0.50+50.00%Beat+188.5%
    Mar 19
    Reported Apr 30
    		$0.62$0.41+51.22%Beat+6300.0%
    Dec 18
    Reported Feb 14
    		$0.40$0.46-13.04%Miss+156.3%
    Sep 18
    Reported Oct 30
    		$0.38$0.41-7.32%Miss+123.5%
    Jun 18
    Reported Jul 31
    		$0.26$0.22+18.18%Beat+533.3%
    Mar 18
    Reported May 1
    		$-0.01N/A-108.33%Miss+99.0%
    Dec 17
    Reported Feb 15
    		$-0.71$-0.45-57.78%Miss-1520.0%
    Sep 17
    Reported Oct 31
    		$0.17$0.06+183.33%Beat-
    Jun 17
    Reported Aug 1
    		$-0.06$-0.04-50.00%Miss-
    Mar 17
    Reported May 4
    		$-0.96$-0.88-9.09%Miss-
    Dec 16
    Reported Feb 14
    		$0.05N/A-64.29%Miss-

    Key Metrics

    Valuation
    P/E Ratio13.06EV/EBITDA9.91x
    Price/FCF11.82xFCF Yield8.46%
    Profitability
    Profit Margin27.70%Operating Margin41.90%
    ROE30.70%ROIC22.97%
    Financial Health
    Debt/Equity0.01xInterest Coverage772.97x
    Current Ratio4.59xQuick Ratio4.51x
    Trading Statistics
    Beta0.74Avg Volume1.80M
    52-Week High$132.6052-Week Low$84.02

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$112.60
    SMA 20$118.12
    SMA 50$121.94
    SMA 200$107.43
    EMA 10$113.53
    EMA 20$116.45
    EMA 50$118.74
    EMA 200$108.42

    MACD

    Line: -3.37Signal: -2.74Hist: -0.63

    ADX

    ADX: 26.8+DI: 18.1-DI: 28.5

    Aroon & PSAR

    Aroon Up24.0
    Aroon Down92.0
    PSAR$107.78

    Bollinger Bands

    Upper Band$130.29
    Lower Band$105.94
    %B Position2062%(Upper)
    Band Width0.30

    RSI (14-Day)

    Neutral
    39.7

    Momentum Oscillators

    Stoch %K18.4
    Stoch %D12.7
    Williams %R-70.1
    ROC (10d)-3.3%
    Momentum-3.87
    CCI (20d)-52.8
    MFI (14d)29.4

    Volatility Measures

    ATR (14d)$3.40(3.0%)
    StdDev (20d)6.09
    Hist Vol23.9%(Moderate)

    Volume Flow

    VWAP$113.97
    OBV54.6M
    AD Line26.0M
    CMF (20d)-0.345

    Volume Metrics

    Avg Vol (20d)1.8M
    Vol Ratio1.1x
    VWMA (20d)$117.87

    Pivot Points

    R3$117.37
    R2$114.72
    R1$113.14
    Pivot Point$110.49
    S1$108.91
    S2$106.26
    S3$104.68

    Advanced Oscillators

    TSI-29.49
    Ultimate Osc42.9
    KST-88.00

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.67B$1.27B$1.51B$1.37B$1.22B$1.05B$1.18B$1.14B$1.04B$880.89M$1.01B$919.02M
    Cost of Revenue$104.96M$104.52M$121.17M$99.00M$78.77M$73.19M$88.48M$85.99M$76.63M$60.96M$69.75M$60.09M
    Gross Profit$1.57B$1.17B$1.39B$1.27B$1.14B$979.71M$1.09B$1.05B$967.13M$819.93M$943.59M$858.93M
    Operating Expenses$871.18M$867.04M$1.05B$823.46M$606.45M$774.54M$788.70M$905.79M$1.45B$728.03M$756.32M$644.23M
    R&D$516.95M$515.90M$611.37M$506.58M$494.92M$437.28M$466.03M$573.17M$1.14B$429.26M$444.49M$375.71M
    SG&A$351.74M$328.09M$390.41M$329.08M$331.02M$325.69M$326.71M$309.21M$305.98M$300.26M$288.23M$267.89M
    Operating Income$697.90M$301.12M$335.86M$443.52M$530.31M$205.17M$301.51M$146.09M$-478,130,000$91.90M$187.27M$214.71M
    Interest Income$47.92M$40.28M$49.00M$35.34M$20.98M$21.59M$11.02M$6.28M$80.72M$146.72M$192.47M$-26,654,000
    Interest Expense$582,000$569,000$582,000$592,000$594,000$660,000$419,000$774,000$657,000$430,000$804,000$623,000
    Income Before Tax$751.51M$343.60M$389.94M$482.31M$558.01M$234.19M$313.72M$156.52M$-389,777,000$236.16M$270.96M$233.80M
    Income Tax Expense$165.91M$40.27M$90.66M$58.14M$153.01M$75.99M$112.51M$50.07M$54.82M$66.61M$69.88M$62.53M
    Net Income$585.61M$303.33M$299.28M$424.17M$405.00M$158.20M$201.21M$106.46M$-444,601,000$169.55M$201.08M$171.27M
    EBITDA$730.65M$327.69M$365.50M$471.58M$560.54M$235.63M$325.86M$173.53M$-447,789,000$111.82M$101.05M$282.47M
    EBIT$704.17M$303.89M$341.52M$447.56M$537.62M$213.26M$303.13M$151.01M$-469,837,000$89.87M$79.29M$261.08M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    Incyte’s Earnings: Strong Growth Amid Market Overlook

    INCY generates $1.17B annual FCF with 93% gross margins and zero leverage, yet trades at 15.6x earnings. Reverse-DCF implies ~0% growth priced in. Quality Score 100/100 with ROIC 25.4%, Piotroski 8/9, interest coverage 702x...

    Glenn Ford
    •
    2/11/26
    •
    147
    Biotech, Healthcare Stocks
    Also mentions:
    NVSLLYREGNGILD

    News

    H.C. Wainwright reiterates Incyte stock rating citing KRAS data

    H.C. Wainwright reiterated a Buy rating and $152 price target for Incyte (NASDAQ: INCY) following promising clinical data from Verastem's KRAS G12D inhibitor program. The firm highlighted Verastem's VS-7375 drug's...

    Investing.com•10/16/26•Bullish

    Incyte Corporation (INCY) Options Chain

    This article provides an options chain for Incyte Corporation (INCY) from Yahoo Finance, displaying real-time price data and options contracts. It indicates that there are currently no calls or puts listed as "In...

    Yahoo! Finance Canada•10/15/26•Neutral

    Incyte Corp. stock outperforms competitors on strong trading day

    Incyte Corp. (INCY) stock advanced by 2.72% to $111.57 on Wednesday, outperforming the broader market during a grim trading session where the S&P 500 Index and Dow Jones Industrial Average both fell. This rise broke...

    MarketWatch•10/14/26•Neutral

    Exelixis, Inc. (EXEL) stock price, news, quote and history

    This article provides a comprehensive overview of Exelixis, Inc. (EXEL), including its current stock price, financial statistics, and company profile. It details the company's oncology-focused operations...

    Yahoo Finance Singapore•10/14/26•Neutral

    Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (FDMT), Pfizer (PFE) and Incyte (INCY)

    This article discusses recent analyst ratings for three healthcare companies: 4D Molecular Therapeutics (FDMT), Pfizer (PFE), and Incyte (INCY). Barclays maintained a Buy rating on FDMT with a $28 price target...

    The Globe and Mail•10/14/26•Somewhat-Bullish

    INCY Valuation and Fair Value

    P/E
    13.1x
    Forward P/E
    14.7x
    EV/EBITDA
    9.9x
    P/FCF
    11.8x
    PEG
    10.8x
    P/B
    3.6x
    See GNG's fair value

    INCY Profitability: Margins, ROIC and FCF

    Gross margin
    92.6%
    Operating margin
    41.9%
    Net margin
    27.7%
    ROIC
    23.0%
    ROE
    30.7%
    FCF margin
    33.0%
    FCF yield
    8.5%

    INCY Competitors

    CompanyTicker
    Genmab ASGMAB
    Tenet Healthcare CorporationTHC
    United Therapeutics CorporationUTHR
    Insmed IncINSM
    Koninklijke Philips NV ADRPHG
    STERIS plcSTE
    Roivant Sciences LtdROIV
    Viatris IncVTRS

    Sector: Healthcare

    INCY Analyst Ratings

    Consensus
    Hold
    Analysts
    28
    Strong Buy
    2
    Buy
    10
    Hold
    15
    Sell
    1
    Strong Sell
    0

    INCY Bull Case vs Bear Case

    Bull case

    • INCY earns a 23.0% return on invested capital.
    • INCY converts 33.0% of revenue into free cash flow.
    • INCY has a 27.7% net profit margin.

    INCY Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    16.9%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-3.63
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 8 down

    Frequently Asked Questions About INCY

    Does INCY pay dividends?

    Incyte Corporation (INCY) does not currently pay a regular dividend.

    What is INCY's P/E ratio?

    Incyte Corporation has a price-to-earnings (P/E) ratio of 13.06.

    What is INCY's market cap?

    Incyte Corporation (INCY) has a market capitalization of $22.61B with a current stock price of $113.27.

    Related stocks

    Sector: Healthcare

    All stocks starting with I

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In